Mary E Sherlock, Thomas Walters, Merit M Tabbers, Karen Frost, Mary Zachos, Aleixo Muise, Elena Pope, Anne M Griffiths
BACKGROUND: Infliximab (IFX), an established therapy for pediatric Crohn disease (CD), is also efficacious in treating psoriasis, a skin disorder, in which tumor necrosis factor-α is implicated pathogenically. Paradoxically, there have been numerous reports of new-onset psoriasis following tumor necrosis factor-α antagonist therapy in adult patients with inflammatory bowel disease, but pediatric data are sparse. METHODS: A retrospective review of all IFX-treated patients with CD, who subsequently developed psoriasis, at a single pediatric inflammatory bowel disease center, was performed...
May 2013: Journal of Pediatric Gastroenterology and Nutrition